Literature DB >> 19380307

Concurrent dual allergen exposure and its effects on airway hyperresponsiveness, inflammation and remodeling in mice.

Franco A DiGiovanni1, Russ Ellis, Jennifer Wattie, Jeremy A Hirota, David S Southam, Mark D Inman.   

Abstract

Experimental mouse models of asthma have broadened our understanding of the mechanisms behind allergen-induced asthma. Typically, mouse models of allergic asthma explore responses to a single allergen; however, patients with asthma are frequently exposed to, and tend to be allergic to, more than one allergen. The aim of the current study was to develop a new and more relevant mouse model of asthma by measuring the functional, inflammatory and structural consequences of chronic exposure to a combination of two different allergens, ovalbumin (OVA) and house dust mite (HDM), in comparison with either allergen alone. BALB/c mice were sensitized and exposed to OVA, HDM or the combination of HDM and OVA for a period of 10 weeks. Following allergen exposure, airway responsiveness was measured using the flexiVent small animal ventilator, and mice were assessed for indices of airway inflammation and remodeling at both 24 hours and 4 weeks after the final allergen exposure. Mice exposed to the HDM-OVA combination exhibited increased numbers of inflammatory cells in the bronchoalveolar lavage (BAL) when compared with mice exposed to a single allergen. Mice exposed to HDM-OVA also exhibited an elevated level of lung tissue mast cells compared with mice exposed to a single allergen. Following the resolution of inflammatory events, mice exposed to the allergen combination displayed an elevation in the maximal degree of total respiratory resistance (Max R(RS)) compared with mice exposed to a single allergen. Furthermore, trends for increases in indices of airway remodeling were observed in mice exposed to the allergen combination compared with a single allergen. Although concurrent exposure to HDM and OVA resulted in increased aspects of airway hyperresponsiveness, airway inflammation and airway remodeling when compared with exposure to each allergen alone, concurrent exposure did not result in a substantially more robust mouse model of allergic asthma than exposure to either allergen alone.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19380307      PMCID: PMC2675793          DOI: 10.1242/dmm.001859

Source DB:  PubMed          Journal:  Dis Model Mech        ISSN: 1754-8403            Impact factor:   5.758


  35 in total

Review 1.  Molecular mechanisms of phenotypic plasticity in smooth muscle cells.

Authors:  A J Halayko; J Solway
Journal:  J Appl Physiol (1985)       Date:  2001-01

Review 2.  Intrinsic properties of allergens and environmental exposure as determinants of allergenicity.

Authors:  A Pomés
Journal:  Allergy       Date:  2002-08       Impact factor: 13.146

Review 3.  Airway hyperresponsiveness.

Authors:  Paul M O'Byrne; Mark D Inman
Journal:  Chest       Date:  2003-03       Impact factor: 9.410

4.  Differential effects of extracellular matrix proteins on human airway smooth muscle cell proliferation and phenotype.

Authors:  S J Hirst; C H Twort; T H Lee
Journal:  Am J Respir Cell Mol Biol       Date:  2000-09       Impact factor: 6.914

5.  A protease-activated pathway underlying Th cell type 2 activation and allergic lung disease.

Authors:  Farrah Kheradmand; Attila Kiss; Jie Xu; Seung-Hyo Lee; Pappachan E Kolattukudy; David B Corry
Journal:  J Immunol       Date:  2002-11-15       Impact factor: 5.422

6.  CD4(+) T-lymphocytes regulate airway remodeling and hyper-reactivity in a mouse model of chronic asthma.

Authors:  Paul S Foster; Ming Yang; Cristan Herbert; Rakesh K Kumar
Journal:  Lab Invest       Date:  2002-04       Impact factor: 5.662

7.  Chronic exposure to innocuous antigen in sensitized mice leads to suppressed airway eosinophilia that is reversed by granulocyte macrophage colony-stimulating factor.

Authors:  Filip K Swirski; Dusan Sajic; Clinton S Robbins; Beata U Gajewska; Manel Jordana; Martin R Stämpfli
Journal:  J Immunol       Date:  2002-10-01       Impact factor: 5.422

8.  Morphometric analysis of mouse airways after chronic allergen challenge.

Authors:  Russ Ellis; Richard Leigh; David Southam; Paul M O'Byrne; Mark D Inman
Journal:  Lab Invest       Date:  2003-09       Impact factor: 5.662

9.  A novel mouse model of experimental asthma.

Authors:  Sampson B Sarpong; Liu-Yi Zhang; Steven R Kleeberger
Journal:  Int Arch Allergy Immunol       Date:  2003-12       Impact factor: 2.749

10.  Dysfunction and remodeling of the mouse airway persist after resolution of acute allergen-induced airway inflammation.

Authors:  Richard Leigh; Russ Ellis; Jennifer Wattie; David S Southam; Meta De Hoogh; Jack Gauldie; Paul M O'Byrne; Mark D Inman
Journal:  Am J Respir Cell Mol Biol       Date:  2002-11       Impact factor: 6.914

View more
  11 in total

1.  The tumor necrosis factor family member LIGHT is a target for asthmatic airway remodeling.

Authors:  Taylor A Doherty; Pejman Soroosh; Naseem Khorram; Satoshi Fukuyama; Peter Rosenthal; Jae Youn Cho; Paula S Norris; Heonsik Choi; Stefanie Scheu; Klaus Pfeffer; Bruce L Zuraw; Carl F Ware; David H Broide; Michael Croft
Journal:  Nat Med       Date:  2011-04-17       Impact factor: 53.440

2.  Lung Pathologies in a Chronic Inflammation Mouse Model Are Independent of Eosinophil Degranulation.

Authors:  Elizabeth A Jacobsen; Sergei I Ochkur; Alfred D Doyle; William E LeSuer; Wen Li; Cheryl A Protheroe; Dana Colbert; Katie R Zellner; HuaHao H Shen; Charles G Irvin; James J Lee; Nancy A Lee
Journal:  Am J Respir Crit Care Med       Date:  2017-05-15       Impact factor: 21.405

3.  Role of LTB₄ in the pathogenesis of elastase-induced murine pulmonary emphysema.

Authors:  Y Michael Shim; Mikell Paige; Halim Hanna; Su H Kim; Marie D Burdick; Robert M Strieter
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2010-09-03       Impact factor: 5.464

4.  Multi-allergen challenge stimulates steriod-resistant airway inflammation via NF-κB-mediated IL-8 expression.

Authors:  Renping Liu; Jinye Bai; Guoshun Xu; Lingling Xuan; Tianqi Zhang; Aiming Meng; Qi Hou
Journal:  Inflammation       Date:  2013-08       Impact factor: 4.092

5.  Sirtuin 2 enhances allergic asthmatic inflammation.

Authors:  Yong Gyu Lee; Brenda F Reader; Derrick Herman; Adam Streicher; Joshua A Englert; Mathias Ziegler; Sangwoon Chung; Manjula Karpurapu; Gye Young Park; John W Christman; Megan N Ballinger
Journal:  JCI Insight       Date:  2019-02-21

6.  Evaluation of Serum Cytokines Levels and the Role of Cannabidiol Treatment in Animal Model of Asthma.

Authors:  Francieli Vuolo; Fabricia Petronilho; Beatriz Sonai; Cristiane Ritter; Jaime E C Hallak; Antonio Waldo Zuardi; José A Crippa; Felipe Dal-Pizzol
Journal:  Mediators Inflamm       Date:  2015-05-25       Impact factor: 4.711

7.  Lung-homing of endothelial progenitor cells and airway vascularization is only partially dependant on eosinophils in a house dust mite-exposed mouse model of allergic asthma.

Authors:  Nirooya Sivapalan; Jennifer Wattie; Mark D Inman; Roma Sehmi
Journal:  PLoS One       Date:  2014-10-03       Impact factor: 3.240

8.  A novel microbe-based treatment that attenuates the inflammatory profile in a mouse model of allergic airway disease.

Authors:  Mark Bazett; Agnieszka Biala; Ryan D Huff; Momir Bosiljcic; Hal Gunn; Shirin Kalyan; Jeremy A Hirota
Journal:  Sci Rep       Date:  2016-10-13       Impact factor: 4.379

9.  A purinergic P2Y6 receptor agonist prodrug modulates airway inflammation, remodeling, and hyperreactivity in a mouse model of asthma.

Authors:  Anne Chetty; Azeem Sharda; Rod Warburton; Ellen O Weinberg; Jinghui Dong; Min Fang; G Gary Sahagian; Tiangmeng Chen; Chang Xue; John J Castellot; Philip G Haydon; Heber C Nielsen
Journal:  J Asthma Allergy       Date:  2018-08-01

10.  Amelioration of ovalbumin-induced allergic airway disease following Der p 1 peptide immunotherapy is not associated with induction of IL-35.

Authors:  D M Moldaver; M S Bharhani; J N Wattie; R Ellis; H Neighbour; C M Lloyd; M D Inman; M Larché
Journal:  Mucosal Immunol       Date:  2013-08-14       Impact factor: 7.313

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.